Essais cliniques

Sans recherche, pas de nouveaux traitements! Or, l’Institut de cardiologie de l’Université d’Ottawa (ICUO) est à cet égard un terrain d’autant plus fertile que sa recherche, si elle s’amorce et s’achève comme toute autre dans un laboratoire, a la particularité de se poursuivre et de se compléter au chevet des patients.

Jusqu’à 200 essais cliniques se déroulent à tout moment à l’ICUO à différentes étapes des études en cours. Nous sommes parfois à l’origine de ces études et les seuls à les mener. Nous collaborons aussi avec d’autres établissements à de vastes recherches d’envergure nationale ou internationale, qu’il nous arrive de diriger. Chaque année, des milliers de volontaires, pour la plupart des patients, mais aussi des personnes en bonne santé, participent à nos études. À l’heure actuelle, 50 scientifiques et chercheurs cliniques mènent des essais cliniques dans nos locaux.

Pour plus d’informations, contactez JoinAStudy@ottawaheart.ca

Essais cliniques à l’Institut de cardiologie de l’Université d’Ottawa (en anglais seulement)

Remarque : La liste ci-dessous contient des projets qui ne sont pas menés à l'Institut de cardiologie, ainsi que des doublons. Nous travaillons à résoudre ce problème.
Filter Status:
Status Study
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

  • Conditions: Non-melanoma Skin Cancer Carcinoma, Squamous Cell Carcinoma, Basal Cell Keratinocyte Carcinoma
  • Sponsor: Women's College Hospital Canadian Institutes of Health Research (CIHR) University Health Network, Toronto NOW Foods
Recruiting

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

  • Conditions: Non-melanoma Skin Cancer Carcinoma, Squamous Cell Carcinoma, Basal Cell Keratinocyte Carcinoma
  • Sponsor: Women's College Hospital Canadian Institutes of Health Research (CIHR) University Health Network, Toronto NOW Foods
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen